October 14, 2014October 16, 2014

Pfizer’s Palbociclib Granted FDA Priority Review For ER+ Breast Cancer Treatment

News

Pfizer Inc. has announced that the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). ... Read more

August 28, 2014August 28, 2014

Pfizer Enrolls HR+, HER2- Advanced Breast Cancer Patients in Palbociclib Expanded Access Program

Breast Cancer News, News

Pfizer is preparing to initiate a multi-center, open-label expanded access program (EAP) for an investigational treatment for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) ... Read more